Literature DB >> 29622943

Management and Preventive Measures for Febrile Neutropenia.

Austin J Lucas, Jacqueline L Olin, Megan D Coleman.   

Abstract

Febrile neutropenia (FN) is an oncological emergency and serious complication often resulting from chemotherapy. In patients with a weak or completely suppressed immune system, a fever may be the only sign of an underlying infection and immediate treatment is needed. Using risk evaluation scores, it is possible to stratify individual patient degree of risk. However, all patients warrant immediate antibiotic coverage. Antibiotic treatment of FN is broadened or narrowed based on individualized clinical scenarios. Prophylactic antimicrobials may be used in specific high-risk situations. This article briefly reviews FN, describes risk assessment tools, and discusses treatment and prophylactic options.

Entities:  

Year:  2018        PMID: 29622943      PMCID: PMC5871243     

Source DB:  PubMed          Journal:  P T        ISSN: 1052-1372


  18 in total

1.  Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.

Authors:  Otavio A C Clark; Gary H Lyman; Aldemar A Castro; Luciana G O Clark; Benjamin Djulbegovic
Journal:  J Clin Oncol       Date:  2005-06-20       Impact factor: 44.544

2.  Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.

Authors:  Christopher J Coyne; Vivian Le; Jesse J Brennan; Edward M Castillo; Rebecca A Shatsky; Karen Ferran; Stephanie Brodine; Gary M Vilke
Journal:  Ann Emerg Med       Date:  2016-12-29       Impact factor: 5.721

3.  Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.

Authors:  J Klastersky; J de Naurois; K Rolston; B Rapoport; G Maschmeyer; M Aapro; J Herrstedt
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

4.  Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.

Authors:  Derek Weycker; Richard Barron; Alex Kartashov; Jason Legg; Gary H Lyman
Journal:  J Oncol Pharm Pract       Date:  2013-07-02       Impact factor: 1.809

5.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

6.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors:  J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

7.  Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors.

Authors:  Derek Weycker; Xiaoyan Li; John Edelsberg; Rich Barron; Alex Kartashov; Hairong Xu; Gary H Lyman
Journal:  J Oncol Pract       Date:  2014-12-09       Impact factor: 3.840

Review 8.  Management of febrile neutropenia in the era of bacterial resistance.

Authors:  Sehnaz Alp; Murat Akova
Journal:  Ther Adv Infect Dis       Date:  2013-02

Review 9.  Colony-stimulating factors for febrile neutropenia during cancer therapy.

Authors:  Charles L Bennett; Benjamin Djulbegovic; LeAnn B Norris; James O Armitage
Journal:  N Engl J Med       Date:  2013-03-21       Impact factor: 91.245

10.  Distinct inflammatory mediator patterns characterize infectious and sterile systemic inflammation in febrile neutropenic hematology patients.

Authors:  Christine Wennerås; Lars Hagberg; Rune Andersson; Lars Hynsjö; Anders Lindahl; Marcin Okroj; Anna M Blom; Peter Johansson; Björn Andreasson; Johan Gottfries; Agnes E Wold
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

View more
  13 in total

1.  A multinational, drug utilization study of lipegfilgrastim use in real-world setting in Europe.

Authors:  Sigal Kaplan; Dana Ilic Bogojevic; Carolyn Rainville; Nicholas Gross
Journal:  Support Care Cancer       Date:  2022-08-31       Impact factor: 3.359

2.  Simple predictors of the re- occurrence of severe febrile neutropenia episode: a single-center retrospective cohort study in pediatric patients with malignant diseases.

Authors:  Silvije Šegulja; Alen Ružić; Dora Dujmić; Ksenija Baždarić; Jelena Roganović
Journal:  Croat Med J       Date:  2019-02-28       Impact factor: 2.415

3.  Advanced Practice Perspectives on Preventing and Managing Tumor Lysis Syndrome and Neutropenia in Chronic Lymphocytic Leukemia.

Authors:  Amy Goodrich
Journal:  J Adv Pract Oncol       Date:  2021-01-01

4.  Sepsis in patients with haematological versus solid cancer: a retrospective cohort study.

Authors:  Ralphe Bou Chebl; Rawan Safa; Mohammad Sabra; Ali Chami; Iskandar Berbari; Sarah Jamali; Maha Makki; Hani Tamim; Gilbert Abou Dagher
Journal:  BMJ Open       Date:  2021-02-16       Impact factor: 2.692

5.  Predictive Factors of Severe Adverse Events in Pediatric Oncologic Patients with Febrile Neutropenia.

Authors:  Jutarat Thangthong; Suvaporn Anugulruengkitt; Supanun Lauhasurayotin; Kanhatai Chiengthong; Hansamon Poparn; Darintr Sosothikul; Piti Techavichit
Journal:  Asian Pac J Cancer Prev       Date:  2020-12-01

6.  Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer.

Authors:  Hsuan-Ming Yao; Sarah Ruta Jones; Serafin Morales; Shahrzad Moosavi; Jeffrey Zhang; Amy Freyman; Faith D Ottery
Journal:  Cancer Chemother Pharmacol       Date:  2021-10-07       Impact factor: 3.333

7.  Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor.

Authors:  Osama Alshari; Yazan O Al Zu'bi; Ahmed H Al Sharie; Farouk H Wafai; Abdelwahab J Aleshawi; Farah H Atawneh; Hasan A Obeidat; Majd N Daoud; Mohammad Z Khrais; Dima Albals; Faize Tubaishat
Journal:  Ther Clin Risk Manag       Date:  2021-09-07       Impact factor: 2.423

8.  Targeting GGT1 Eliminates the Tumor-Promoting Effect and Enhanced Immunosuppressive Function of Myeloid-Derived Suppressor Cells Caused by G-CSF.

Authors:  Zhiqi Xie; Takahiro Kawasaki; Haoyang Zhou; Daisuke Okuzaki; Naoki Okada; Masashi Tachibana
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

9.  Dapsone as a Detrimental Cause of Necrotizing Fasciitis With Severe Resistant Neutropenia: A Case Report.

Authors:  Juwairiah Abdur Raheem; Arshiya Unnisa; Mohammed Iqubal
Journal:  Cureus       Date:  2022-03-11

Review 10.  Carbapenem-Resistant Enterobacteriaceae-Implications for Treating Acute Leukemias, a Subgroup of Hematological Malignancies.

Authors:  Kristin Ølfarnes Storhaug; Dag Harald Skutlaberg; Bent Are Hansen; Håkon Reikvam; Øystein Wendelbo
Journal:  Antibiotics (Basel)       Date:  2021-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.